Brian Peter Zambrowicz
Directeur/Membre du Conseil chez Texas A&M Institute for Genomic Medicine
Profil
Brian Peter Zambrowicz is the founder of Lexicon Pharmaceuticals, Inc. which was founded in 1995.
He held the title of Chief Scientific Officer & Executive VP from 2011 to 2015.
Currently, he is the Director at Texas A&M Institute for Genomic Medicine.
He previously worked as a Director & Senior Scientific Advisor at Nuevolution AB.
Dr. Zambrowicz earned a doctorate degree from the University of Washington and an undergraduate degree from the University of Wisconsin.
Postes actifs de Brian Peter Zambrowicz
| Sociétés | Poste | Début |
|---|---|---|
Texas A&M Institute for Genomic Medicine
 Texas A&M Institute for Genomic Medicine Miscellaneous Commercial ServicesCommercial Services Texas A&M Institute for Genomic Medicine focuses in research and development for medical industry. It was founded in 2006 and is headquartered in College Station, Texas. | Directeur/Membre du Conseil | - |
Anciens postes connus de Brian Peter Zambrowicz
| Sociétés | Poste | Fin |
|---|---|---|
| LEXICON PHARMACEUTICALS, INC. | Fondateur | 24/02/2015 |
| NUEVOLUTION AB (PUBL) | Directeur/Membre du Conseil | - |
Formation de Brian Peter Zambrowicz
| University of Washington | Doctorate Degree |
| University of Wisconsin | Undergraduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| LEXICON PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Nuevolution AB
 Nuevolution AB Pharmaceuticals: MajorHealth Technology Nuevolution AB engages in pharmaceutical and biotechnology discovery. Its activities include research and development, and licensing drugs and treatment of oncology and chronic inflammatory diseases including cancer. It offers the platform Chemetics, which enables discovery of small molecule drug candidates for specific indications addressing target diseases. The company was founded by Henrik Pedersen, Alex Haahr Gouliaev, and Mads Nørregaard-Madsen in May 2001 and is headquartered in Copenhagen, Denmark. | Health Technology |
Texas A&M Institute for Genomic Medicine
Texas A&M Institute for Genomic Medicine Miscellaneous Commercial ServicesCommercial Services Texas A&M Institute for Genomic Medicine focuses in research and development for medical industry. It was founded in 2006 and is headquartered in College Station, Texas. | Commercial Services |